Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Finance Minister: Sanae Takaichi is not a "reflationist" and highly respects the independence of the central bank
The Japanese Finance Minister stated that Ms. Komei herself has repeatedly requested her to clarify this position to overseas investors. This statement attempts to dispel the market’s perception that the Komei government interferes with the central bank or pursues a loose monetary policy. Last Wednesday, two committee members nominated by Komei opposed a Bank of Japan interest rate hike, further reinforcing the market’s view that the Japanese government tends to delay rate increases.
HIFI Raises $37M Series A to Build Settlement Rails for Tokenized Money
Crypto prices
More
